Change over period: —
NSE · WINDLAS
WINDLAS
-14.4% from the 52-week high · +40.1% above the low
Windlas Biotech Ltd. operates as a contract development and manufacturing organization (CDMO). The firm provides a range of contract development and manufacturing organization (CDMO) services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics. Its therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry and respiratory therapies. The Company’s service capabilities include formulation development, technology scale-up and full-scale commercial manufacturing. The company has capabilities for both solid and liquid pharmaceutical dosage forms. The firm markets its own manufactured nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities. The company also has a salesforce and distribution network spread across over 14 states. The Company’s manufacturing facilities are located at Dehradun in Uttarakhand.
The short version. WINDLAS reported revenue of ₹238 crore for Mar 2026, up 17.2% from a year earlier. Net profit was ₹16 crore (up 0.0% year on year). Return on equity was 11.4% in Mar 2026. Promoter holding was 63.31% in Sep 2026, up 0.80 points over 8 quarters.
1 · The price
How has the stock traded?
WINDLAS trades 14.4% below its 52-week high and 40.1% above its 52-week low.
2 · The business
Is it growing?
Mar 2026 revenue of ₹238 cr.
Mar 2026 net profit of ₹16 cr.
1.3 pts lower than a year earlier.
Revenue compounded at 20.8% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 238 | 233 | 222 | 210 | 203 | 195 | 187 | 175 |
| Net profit | 16 | 15 | 18 | 18 | 16 | 16 | 16 | 13 |
| Net margin % | 6.7 | 6.4 | 8.0 | 8.4 | 8.0 | 8.0 | 8.4 | 7.7 |
| EPS (₹) | 7.58 | 7.12 | 8.45 | 8.43 | 7.77 | 7.45 | 7.49 | 6.45 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | 904 | 760 | 631 | 513 | 466 |
| Net profit | 66 | 61 | 58 | 43 | 38 |
| Net margin % | 7.4 | 8.0 | 9.2 | 8.3 | 8.1 |
| EPS (₹) | 31.49 | 29.1 | 27.98 | 20.35 | 17.39 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 11.4% in Mar 2026; debt to equity is 0.05.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 11.4 | 12.1 | 12.9 | 10.6 |
| Return on capital % | 15.7 | 16.5 | 17.2 | 14.2 |
| EBITDA margin % | 13.3 | 14.4 | 14.2 | 13.4 |
| Net margin % | 7.2 | 7.8 | 9.0 | 8.2 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 20.8% | — |
| Profit CAGR | 16.0% | — |
4 · The owners
Who holds it, and are they adding?
Up 0.8 pts over 8 quarters.
Up 0.53 pts over 8 quarters.
Down 3.02 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 62.51 | 62.34 | 62.34 | 61.99 | 61.99 | 61.9 | 63.31 | 63.31 | +0.8 |
| FII | 1.55 | 1.52 | 1.44 | 1.11 | 0.93 | 0.6 | 2.04 | 2.08 | +0.53 |
| DII | 10.26 | 10.89 | 11.21 | 11.43 | 11.44 | 11.81 | 9.84 | 7.24 | -3.02 |
| Public | 25.68 | 25.25 | 25.01 | 25.47 | 25.64 | 25.7 | 24.8 | 27.36 | +1.68 |
Mutual fund holdings · Oct 2026
5 schemes hold this stock
5 the month before.
- UTI - Healthcare Fund1.27% of NAV
- ICICI Prudential Healthcare Fund0.44% of NAV
- Bandhan Small Cap Fund0.05% of NAV
- Motilal Oswal BSE Healthcare ETF0.04% of NAV
- Bandhan BSE Healthcare Index Fund0.04% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for WINDLAS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about WINDLAS
What is the WINDLAS share price?
WINDLAS (WINDLAS) last closed at ₹979.25, down 0.95% on the day. Its 52-week range is ₹705.75 to ₹1,154.75.
What is the market cap of WINDLAS?
WINDLAS has a market capitalisation of about ₹2,040 crore. Its price-to-earnings ratio is 31.6.
How are WINDLAS's latest results?
WINDLAS reported revenue of ₹238 crore for Mar 2026, up 17.2% from a year earlier. Net profit was ₹16 crore (up 0.0% year on year). Return on equity was 11.4% in Mar 2026. Promoter holding was 63.31% in Sep 2026, up 0.80 points over 8 quarters.
Who owns WINDLAS?
As of Sep 2026, shareholding was: Promoter 63.31%, FII 2.08%, DII 7.24%, Public 27.36%.
How many mutual funds hold WINDLAS?
5 mutual fund schemes held WINDLAS in October 2026. That compares with 5 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 21 Jul 2025 · Final Dividend - Rs. 5.8
- 17 Sep 2024 · Dividend - Rs. 5.5
- 05 Sep 2023 · Final Dividend - Rs. 4
- 09 Sep 2022 · Dividend - Rs. 3.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.